Barclays Predicts Oscar Health Will Benefit Most from ACA Boom
Barclays raised Oscar Health rating, sees higher price target as ACA growth and pricing gains boost future profits.
/ 1652 items
#XY↓
Sanofi’s Phase 3 CIDP Failure Hits Riliprubart and Raises Doubts for Dianthus’ Claseprubart
Sanofi discontinues its Phase 3 MOBILIZE study of riliprubart in refractory CIDP after failing to show efficacy. The setback raises major doubts for Dianthus’ claseprubart (C1s inhibitor).
Cellectis Receives FDA RMAT Status for lasme-cel – First Allogeneic CAR-T in Pivotal Trial for r/r B-ALL
Cellectis got FDA RMAT for lasme-cel, an off-the-shelf CAR-T therapy for hard-to-treat leukemia that may speed up patient access.
Perrigo CEO Resigns Over Personal Conduct – Interim Leader Named
Perrigo CEO resigned over conduct issues; interim CEO Albert Manzone appointed; company keeps 2026 sales and earnings targets unchanged.
FDA Greenlights Alterity’s Phase 3 Plan for ATH434 in Multiple System Atrophy
Alterity’s drug ATH434 slowed MSA progression in trials, and FDA-approved Phase 3 plans bring it closer to becoming the first real treatment.
Sephience Sales Momentum Prompts Citi to Upgrade PTC Therapeutics to Buy
Citi turns bullish on PTCT, citing strong Sephience sales in PKU and potential $1B+ peak, raising target to $108.